Review
Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections
H L Greenberg et al. Pediatr Dermatol. 2002 Jan-Feb.
Abstract
The use of antifungal/corticosteroid combinations as topical therapy for dermatophytoses has been criticized as being less effective, more expensive, and the cause of more adverse cutaneous reactions than antifungal monotherapy. The combination of clotrimazole and betamethasone diproprionate (Lotrisone) is a mix of an azole antifungal and a high-potency corticosteroid, and is one of the most widely prescribed of these combinations. Our objective was to describe the beneficial and deleterious effects of Lotrisone in the treatment of common cutaneous fungal infections and its relative cost-effectiveness. We did a literature review documenting clinical trial data and adverse reactions to Lotrisone and collected a cost analysis of topical antifungal prescribing data over a 2-month period from a large midwestern staff-model health maintenance organization (HMO). Lotrisone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of tinea pedis, tinea cruris, and tinea corporis in adults and children more than 12 years of age. Treatment is limited to 2 weeks in the groin area and 4 weeks on the feet. The most concerning adverse effects of Lotrisone were reported in children and included treatment failure, striae distensae, hirsuitism, and growth retardation. This combination was also reported to have decreased efficacy in clearing candidal and Trichophyton infections as compared to single-agent antifungals. Lotrisone was considerably more expensive than clotrimazole alone and was found to account for more than 50% of topical antifungal expenditures as prescribed by primary care physicians, but only 7% of topical antifungals prescribed by dermatologists. We found that Lotrisone was shown to have the potential to induce many steroid-related side effects and to be less cost effective than antifungal monotherapy. This combination should be used judiciously in the treatment of cutaneous fungal infections and may not be appropriate for use in children.
Similar articles
Use of clotrimazole/betamethasone diproprionate by family physicians.
Shaffer MP, Feldman SR, Fleischer AB Jr. Shaffer MP, et al. Fam Med. 2000 Sep;32(8):561-5. Fam Med. 2000. PMID: 11002867
Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents.
Alston SJ, Cohen BA, Braun M. Alston SJ, et al. Pediatrics. 2003 Jan;111(1):201-3. doi: 10.1542/peds.111.1.201. Pediatrics. 2003. PMID: 12509578
Topical antifungal treatments for tinea cruris and tinea corporis.
El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, Moore M, Little P. El-Gohary M, et al. Cochrane Database Syst Rev. 2014 Aug 4;(8):CD009992. doi: 10.1002/14651858.CD009992.pub2. Cochrane Database Syst Rev. 2014. PMID: 25090020 Review.
Topical treatment of common superficial tinea infections.
Weinstein A, Berman B. Weinstein A, et al. Am Fam Physician. 2002 May 15;65(10):2095-102. Am Fam Physician. 2002. PMID: 12046779 Review.
Cited by
Clotrimazole as a Cancer Drug: A Short Review.
Kadavakollu S, Stailey C, Kunapareddy CS, White S. Kadavakollu S, et al. Med Chem (Los Angeles). 2014;4(11):722-724. doi: 10.4172/2161-0444.1000219. Med Chem (Los Angeles). 2014. PMID: 26819835 Free PMC article.
[Local combination therapy of inflammatory dermatomycosis: A review of recommendations in national and international guidelines].
Czaika VA, Zuberbier T. Czaika VA, et al. Hautarzt. 2015 May;66(5):360-9. doi: 10.1007/s00105-015-3597-x. Hautarzt. 2015. PMID: 25939891 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations